N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins
about
Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate.Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-α/Fc fusion proteins expressed in Pichia pastoris.Maternal and Fetal Mechanisms of B Cell Regulation during Pregnancy: Human Chorionic Gonadotropin Stimulates B Cells to Produce IL-10 While Alpha-Fetoprotein Drives Them into ApoptosisAn unexpected N-terminal loop in PD-1 dominates binding by nivolumab.Human protein secretory pathway genes are expressed in a tissue-specific pattern to match processing demands of the secretome.A system identification approach for developing model predictive controllers of antibody quality attributes in cell culture processes.Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy.Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.Characterization of Aggregation Propensity of a Human Fc-Fusion Protein Therapeutic by Hydrogen/Deuterium Exchange Mass Spectrometry.Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.Metabolic engineering of CHO cells for the development of a robust protein production platform.Pharmacokinetics of Monoclonal Antibodies.Site-specific monitoring of N-Glycosylation profiles of a CTLA4-Fc-fusion protein from the secretory pathway to the extracellular environment.Aminolated and Thiolated PEG-Covered Gold Nanoparticles with High Stability and Antiaggregation for Lateral Flow Detection of Bisphenol A.The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins.Recombinant Proteins and Monoclonal Antibodies.Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies.Purification Methods for Recombinant Factor VIII Expressed in Human Liver SK-Hep Cells.Restricted processing of CD16a/Fc γ receptor IIIa N-glycans from primary human NK cells impacts structure and function.A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.Genetic disruption of multiple α1,2-mannosidases generates mammalian cells producing recombinant proteins with high-mannose-type N-glycans.A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells.Multi-Compartment and Multi-Host Vector Suite for Recombinant Protein Expression and Purification.
P2860
Q33459216-01C19C7E-3EDC-4178-976A-298C38850958Q37481254-F3A3C87E-F190-47C4-8AA8-B09C3BDFDBE6Q37483942-EA470125-78C2-43AA-A73D-E31996F3F4B2Q37637845-469EC9A5-94A0-4A6B-AA72-10B0DB24E4C4Q38606264-F9977083-D720-41E9-9B8B-4A46487F283AQ38635373-13B06B79-50B3-4507-AF7A-4D5E4B30DBD8Q38762019-C8C9DD46-D396-4734-9E24-A5AEBAB9F0E0Q38974661-0E927C9E-48BA-430A-8B7B-BD33AF4BF569Q39361301-5B8F19C7-2666-4B21-A849-78B022739FBEQ39488460-BE0D8B8E-F2A4-4368-A43C-A120AEB7895FQ41140868-E5B3A425-D6A9-4EE3-99D3-22A3DEAE95CFQ41200443-759AE75F-FDC4-4A65-825A-A866BFBD5627Q42118646-6803224B-C690-4D21-B8E6-8C81383CE56EQ46419886-9E7B1440-5D21-4579-8F7F-D36C27120BD2Q47216758-E23FDE14-5C29-4EAF-991E-5687E3C75040Q47410418-0EAA2773-44F3-4B5F-BD0B-F86054CC31A1Q47602370-A51D51C7-576D-4113-B497-F7ADBEAB9049Q47732599-E4394F25-06CD-4E0C-A53F-FAC48E66C8F3Q47786825-EAABC3FF-9A3B-4D3C-BD09-36876FB916E4Q50058989-5B7F91D8-6895-4DED-9010-1CC6526EAC5FQ50199955-A1DE6D36-090B-4ACD-9546-6B89E6E34D9FQ52373727-EA4FB264-631B-497A-A86D-3350050630EBQ52586580-65E4F3F4-2802-42FE-96CE-988A7B316E50Q55537027-2024CBB3-EB6D-4FDA-978B-8B70B89392D7
P2860
N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@ast
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@en
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@nl
type
label
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@ast
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@en
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@nl
prefLabel
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@ast
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@en
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@nl
P2093
P921
P1476
N-glycosylation heterogeneity ...... ibodies and Fc fusion proteins
@en
P2093
Andreas Seidl
Fabian Higel
Fritz Sörgel
Wolfgang Friess
P304
P356
10.1016/J.EJPB.2016.01.005
P407
P577
2016-03-01T00:00:00Z